TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 5, 2025; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| New patient prescriptions | 36% | second quarter of 2026 | — |
| Refills | 207% | second quarter of 2026 | — |
| Total coverage for TONMYA across commercial, managed Medicare, and Medicaid channels | 136M | second quarter of 2026 | — |
| Total prescriptions | 12,592 | second quarter of 2026 | — |
| prescriptions were filled | 5,400 | Q1 2026 | — |
| unique healthcare providers prescribed TONMYA to patients | 2,145 | Q1 2026 | — |
| unique patients initiated treatment with TONMYA | 3,588 | Q1 2026 | — |
| shares of common stock outstanding | 12,793,952 | January 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNXP
this stock
Tonix Pharmaceuticals Holding Corp.
|
$213.53M | -20.3% | +29.8% | — | 19.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +7.3% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +21.2% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Feb 5, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNXP | -1.7% | +20.1% | -10.7% | +24.4% | -20.3% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | -0.5% | +16.8% | -22.9% | +22.2% | -32.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.